{"id":"W3136856529","doi":"10.1158/1538-7445.sabcs20-pd3-03","title":"Abstract PD3-03: Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Oncology; Breast cancer; Internal medicine; Trastuzumab; Hazard ratio; Placebo; Stage (stratigraphy); Cancer; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001244545,0.0003001159,0.001482204,0.0002401175,0.0001416727,0.00007457191,0.0002888818,0.000116211,0.00256328],"category_scores_gemma":[0.0003571397,0.0001978915,0.0003356264,0.001467239,0.0006668738,0.0001657648,0.0000985641,0.0008661699,0.000005287855],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004443942,"about_ca_system_score_gemma":0.001269726,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02575856,"about_ca_topic_score_gemma":0.004824146,"domain_scores_codex":[0.9954515,0.001021607,0.0006989431,0.0006946639,0.001488207,0.0006450859],"domain_scores_gemma":[0.9954305,0.00202005,0.0002926921,0.0006969258,0.001358416,0.000201431],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9106244,0.001413623,0.06791645,0.00003695741,0.002984958,0.00009270987,0.001422793,0.0006495906,0.002672995,0.00003448623,0.00005893581,0.01209203],"study_design_scores_gemma":[0.5113978,0.0002813865,0.4849312,0.0002974659,0.000389467,5.359977e-7,0.0001702392,0.00005657026,0.00215633,0.00001962442,0.0001504004,0.0001489581],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924301,0.001516754,0.00007973093,0.001323488,0.0001727819,0.002213926,0.002081703,0.00001904443,0.0001624732],"genre_scores_gemma":[0.9974646,0.0003078002,0.0001159275,0.0001168385,0.0005077472,0.0005370306,0.0003749524,0.00005035933,0.0005247752],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4170147,"threshold_uncertainty_score":0.9983485,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04989331607234977,"score_gpt":0.4014012699091703,"score_spread":0.3515079538368205,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}